MCID: CDQ001
MIFTS: 42

Cauda Equina Syndrome malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cauda Equina Syndrome

About this section

Aliases & Descriptions for Cauda Equina Syndrome:

Name: Cauda Equina Syndrome 10 45 12 65
Polyradiculopathy 36 65
 
Cauda Equina 47

Classifications:



External Ids:

Disease Ontology10 DOID:11577
ICD1027 G83.4
ICD9CM29 344.6
MeSH36 D011128
NCIt42 C35436
UMLS65 C0392548

Summaries for Cauda Equina Syndrome

About this section
NIH Rare Diseases:45 Cauda equina syndrome refers to a group of symptoms that occur when some of the nerves in the cauda equina (the bundle of nerves that spread out from the bottom of the spinal cord) become compressed and/or damaged. signs and symptoms of this condition include pain, numbness, or tingling in the lower back and/or legs; "foot drop"; problems with bowel and/or bladder control; and sexual dysfunction. cauda equina syndrome may be caused by a herniated disk, tumor, infection, fracture, or spinal stenosis. treatment usually targets the underlying cause of the condition and often includes surgery to remove the material that is pressing on the nerves. physical therapy, occupational therapy, and/or other services may be required if symptoms persist following surgery. last updated: 5/17/2015

MalaCards based summary: Cauda Equina Syndrome, also known as polyradiculopathy, is related to leiomyoma and cauda equina neoplasm. An important gene associated with Cauda Equina Syndrome is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6), and among its related pathways are Arachidonate Epoxygenase / Epoxide Hydrolase and Losartan Pathway, Pharmacokinetics. Affiliated tissues include spinal cord, lung and thyroid.

Disease Ontology:10 A peripheral nervous system disease that involves an acute loss of function of the lumbar plexus, neurologic elements (nerve roots) of the spinal canal below the termination (conus) of the spinal cord.

Wikipedia:68 Cauda equina syndrome (CES) is a serious neurologic condition in which damage to the cauda equina causes... more...

Related Diseases for Cauda Equina Syndrome

About this section

Graphical network of the top 20 diseases related to Cauda Equina Syndrome:



Diseases related to cauda equina syndrome

Symptoms for Cauda Equina Syndrome

About this section

Drugs & Therapeutics for Cauda Equina Syndrome

About this section

Drugs for Cauda Equina Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Chloroprocaineapproved15133-16-48612
Synonyms:
133-16-4
2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate
2-(Diethylaminoethyl)-4-amino-2-chlorobenzoate
2-Chloroprocaine
2-diethylaminoethyl 4-amino-2-chlorobenzoate
3858-89-7 (hydrochloride)
4-14-00-01273 (Beilstein Handbook Reference)
4-amino-2-Chlorobenzoic acid 2-(diethylamino)ethyl ester
4-amino-2-chlorobenzoic acid 2-(diethylamino)ethyl ester
AC1L1RCM
BRN 2808071
Benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester
C07877
C13H19ClN2O2
CHEBI:3636
CHLOROPROCAINE
CID8612
Chlor-procaine
Chloroprocain
 
Chloroprocaine
Chloroprocaine (INN)
Chloroprocaine Hydrochloride
Chloroprocaine [INN]
Chloroprocaine hydrochloride
Chloroprocainum
Chloroprocainum [INN-Latin]
Chlorprocaine
Chlorprocainum
Cloroprocaina
Cloroprocaina [INN-Spanish]
D07678
DB01161
HSDB 3301
Halestyn
LS-35706
Nesacaine
Nesacaine MPF
Nesacaine-Ce
Piocaine
UNII-5YVB0POT2H
2
Procaineapproved, investigational3559-46-14914
Synonyms:
.beta.-(Diethylamino)ethyl p-aminobenzoate
.beta.-Diethylaminoethyl 4-aminobenzoate
2-(Diethylamino)ethyl 4-aminobenzoate
2-(Diethylamino)ethyl p-aminobenzoate
2-(Diethylamino)ethyl-4-aminobenzoate
2-Diethylaminoethyl 4-aminobenzoate
2-Diethylaminoethyl p-aminobenzoate
2-Diethylaminoethylester kyseliny p-aminobenzoove
2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]
4-14-00-01138 (Beilstein Handbook Reference)
4-Aminobenzoesaeure-beta-diethylaminoethylester
4-Aminobenzoic acid 2-(diethylamino) ethyl ester
4-Aminobenzoic acid 2-diethylaminoethyl ester
4-Aminobenzoic acid diethylaminoethyl ester
59-46-1
91484-72-9
AB00053531
AC1L1J8C
AC1Q2ZE2
AKOS000115407
Allocaine
Anticort
Anticort (TM)
Anuject
BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE
BPBio1_000179
BRD-K24616672-003-05-2
BRN 0913480
BSPBio_000161
BSPBio_002231
Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester
Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester
C07375
CAS-51-05-8
CHEBI:8430
CHEMBL569
CID4914
D08422
DB00721
Diethylaminoethyl p-aminobenzoate
DivK1c_000120
Duracaine
EINECS 200-426-9
Factor H3
Gerokit
Gerovital
Gerovital H-3
HSDB 3388
I06-1439
IDI1_000120
InChI=1/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H
Jenacain
Jenacaine
KBio1_000120
KBio2_001318
KBio2_003886
KBio2_006454
KBio3_001731
KBioGR_000975
 
KBioSS_001318
LS-35778
Lopac-P-9879
Lopac0_000966
MolPort-000-889-177
NCGC00015864-01
NCGC00015864-02
NCGC00015864-04
NCGC00162298-01
NINDS_000120
NSC 169497
NSC169497
Nissocaine
Norocaine
Novocain
Novocaine
Prestwick0_000041
Prestwick1_000041
Prestwick2_000041
Prestwick3_000041
Procain
Procaina
Procaina [INN-Spanish]
Procaine
Procaine (INN)
Procaine HCl
Procaine Hydrochloride
Procaine [INN:BAN]
Procaine, base
Procainum
Procainum [INN-Latin]
SP-01A
SP01
SP01A
SPBio_001331
SPBio_002082
STK177303
STOCK2S-12721
Scurocaine
Solution of novocain
Solution of novocain (TN)
Spectrum2_001296
Spectrum3_000556
Spectrum4_000488
Spectrum5_001186
Spectrum_000838
Spinocaine
Stoff H3
UNII-4Z8Y51M438
Vitamin H3
WLN: ZR DVO2N2&2
beta-(Diethylamino)ethyl 4-aminobenzoate
beta-(Diethylamino)ethyl P-aminobenzoate
beta-(Diethylamino)ethyl p-aminobenzoate
beta-Diethylaminoethyl 4-aminobenzoate
p-Aminobenzoic acid 2-diethylaminoethyl ester
p-Aminobenzoyldiethylaminoethanol
p-Aminobenzyoyldiethylaminoethanol
procaine
╬▓-(diethylamino)ethyl 4-aminobenzoate
╬▓-(diethylamino)ethyl p-aminobenzoate
3Peripheral Nervous System Agents18510
4Central Nervous System Depressants10016
5Anesthetics, Local2347
6Anesthetics7385

Interventional clinical trials:

idNameStatusNCT IDPhase
1Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)Not yet recruitingNCT02591901Phase 2
2Observational Prospective Study on 2-chloroprocaine Hydrochloride 1% Safety in Intrathecal AnaesthesiaRecruitingNCT02067806
3Peristeen Bowel Irrigation System in Cauda EquinaActive, not recruitingNCT01784328
4Evaluation of Minimally Invasive Microdiscectomy Versus Conventional Open Microdiscectomy For Lumbar Herniated DiscEnrolling by invitationNCT00927056

Search NIH Clinical Center for Cauda Equina Syndrome


Cochrane evidence based reviews: polyradiculopathy

Genetic Tests for Cauda Equina Syndrome

About this section

Anatomical Context for Cauda Equina Syndrome

About this section

MalaCards organs/tissues related to Cauda Equina Syndrome:

33
Spinal cord, Lung, Thyroid, Breast, T cells, Heart, Bone

Animal Models for Cauda Equina Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Cauda Equina Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes

Publications for Cauda Equina Syndrome

About this section

Articles related to Cauda Equina Syndrome:

(show top 50)    (show all 475)
idTitleAuthorsYear
1
Cytological diagnosis of adult T-cell leukemia/lymphoma in sputum. (26972585)
2016
2
Case report on a patient with lupus panniculitis. (25821430)
2015
3
Neuroprotection in acute brain injury: an up-to-date review. (25896893)
2015
4
MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. (24462768)
2014
5
Maternal MTHFR C677T polymorphism and congenital heart defect risk in the Chinese Han population: a meta-analysis. (24338416)
2013
6
The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. (23873689)
2013
7
Genetic susceptibility to primary angle closure glaucoma (PACG). (23375010)
2013
8
Pacemaker lead induced inferior vena caval thrombosis leading to portal hypertension. (23573063)
2013
9
Recurrent corneal erosion following uneventful IntraLASIK treated by phototherapeutic keratectomy. (22180150)
2012
10
p53 codon 72 polymorphisms and random amplified polymorphic DNA analysis of non-melanoma skin cancer through archival formalin-fixed paraffin-embedded tissue. (22159872)
2012
11
Peroxisome proliferator-activated receptors I^/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus. (22849356)
2012
12
Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. (21898069)
2012
13
Functioning and disability in adults with myotonic dystrophy type 1. (21254917)
2011
14
Lack of association of primary iron overload and common HFE gene mutations with liver cirrhosis in adult Indian population. (21822737)
2011
15
Competitive suppression between chikungunya and dengue virus in Aedes albopictus c6/36 cell line. (22299407)
2011
16
Distress and alexithymia in lung recipients - psychosocial strains and associations with chronic allograft dysfunction. (20175005)
2010
17
Functional characterization of Borrelia spielmanii outer surface proteins that interact with distinct members of the human factor H protein family and with plasminogen. (19858303)
2010
18
Serum cortisol concentration and force plate analysis in the assessment of pain associated with sodium urate-induced acute synovitis in dogs. (20673094)
2010
19
Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. (18798225)
2009
20
Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas. (19461527)
2009
21
Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis? (19278365)
2009
22
Focal myositis of the calf muscles. (19032842)
2008
23
The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. (18997494)
2008
24
The cytoskeleton-associated PDZ-LIM protein, ALP, acts on serum response factor activity to regulate muscle differentiation. (17332502)
2007
25
Critical roles for the M3-S2 transduction linker domain in kainate receptor assembly and postassembly trafficking. (17898214)
2007
26
Identification of Epha4 enhancer required for segmental expression and the regulation by Mesp2. (16728472)
2006
27
Anal canal carcinoma with Pagetoid spread: report of a case. (16794808)
2006
28
Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza")]. (16900584)
2006
29
Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. (15876485)
2006
30
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. (15813853)
2005
31
Low-grade tubular-mucinous renal neoplasm with neuroendocrine differentiation: a histological, immunohistochemical and ultrastructural study. (14989744)
2004
32
Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies. (12127130)
2002
33
Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. (11911240)
2001
34
Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. (11497246)
2001
35
HER2: the neu prognostic marker for breast cancer. (11347719)
2001
36
Variations in the human phospholipase Cgamma2 gene in patients with B-cell defects of unknown etiology. (11685467)
2001
37
Successful intrauterine shunting of a sacrococcygeal teratoma (SCT) causing fetal bladder obstruction. (11746122)
2001
38
Role of nitrates for the therapy of coronary artery disease patients in the years beyond 2000. (10499556)
1999
39
Effect of long-term treatment of 3T3-L1 adipocytes with chlorate on the synthesis, glycosylation, intracellular transport and secretion of lipoprotein lipase. (9445371)
1998
40
The prognostic value of concurrent phrenic nerve palsy in newborn children with Erb's palsy. (9607664)
1998
41
Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. (9219044)
1997
42
A case of multiple nevoid hypertrichosis. (9198325)
1997
43
The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. (8648176)
1996
44
Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin-stimulated human platelets. (8663010)
1996
45
How interleukin-2 can affect human fibroblasts behaviour. (7899144)
1994
46
Onset of polymyositis with autoantibodies to threonyl-tRNA synthetase during pregnancy. (7983666)
1994
47
Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. (7818774)
1994
48
In situ hybridization histochemistry of mRNAs for hormones and chromogranins in normal pituitary tissue and pituitary adenoma. (1789058)
1991
49
Pathogenesis of hypertensive retinopathy: a review. (399635)
1979
50
Nephrotic syndrome associated with Fanconi Syndrome. Immunopathogenic studies of tubulointerstitial nephritis with autologous immune-complex glomerulonephritis. (130817)
1976

Variations for Cauda Equina Syndrome

About this section

Expression for genes affiliated with Cauda Equina Syndrome

About this section
Search GEO for disease gene expression data for Cauda Equina Syndrome.

Pathways for genes affiliated with Cauda Equina Syndrome

About this section

Pathways related to Cauda Equina Syndrome according to GeneCards Suite gene sharing:

(show all 22)
idSuper pathwaysScoreTop Affiliating Genes
19.5CYP2C8, CYP2C9
29.5CYP2C9, CYP3A4
39.5CYP2C9, CYP3A4
4
Show member pathways
9.4CYP2C8, CYP3A4
59.4CYP2B6, CYP2C9
69.1AR, CYP3A4
7
Show member pathways
9.0CYP2C8, CYP2C9, CYP3A4
89.0CYP2C8, CYP2C9, CYP3A4
9
Show member pathways
9.0CYP2C8, CYP2C9, CYP3A4
10
Show member pathways
8.9CYP2B6, CYP2D6, CYP3A4
11
Show member pathways
8.9CYP2B6, CYP2D6, CYP3A4
128.9CYP2B6, CYP2C9, CYP3A4
138.9CYP2B6, CYP2C9, CYP3A4
14
Show member pathways
8.6CYP2C8, CYP2C9, CYP2D6, CYP3A4
15
Show member pathways
8.5CYP2B6, CYP2C9, CYP2D6, CYP3A4
16
Show member pathways
8.5CYP2B6, CYP2C9, CYP2D6, CYP3A4
17
Show member pathways
8.4CYP2B6, CYP2C8, CYP2C9, CYP3A4
18
Show member pathways
7.9CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4
19
Show member pathways
7.9CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4
20
Show member pathways
7.9CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4
21
Show member pathways
7.9CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4
22
Show member pathways
7.9CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4

GO Terms for genes affiliated with Cauda Equina Syndrome

About this section

Biological processes related to Cauda Equina Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1arachidonic acid metabolic processGO:00193699.7CYP2C9, CYP2D6
2heterocycle metabolic processGO:00464839.4CYP2D6, CYP3A4
3exogenous drug catabolic processGO:00427389.1CYP2B6, CYP2C9
4monoterpenoid metabolic processGO:00160989.1CYP2C9, CYP2D6, CYP3A4
5epoxygenase P450 pathwayGO:00193738.9CYP2B6, CYP2C8, CYP2C9
6xenobiotic metabolic processGO:00068058.0CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4

Molecular functions related to Cauda Equina Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1monooxygenase activityGO:00044979.4CYP2C8, CYP3A4
2caffeine oxidase activityGO:00348759.3CYP2C8, CYP2C9, CYP3A4
3arachidonic acid epoxygenase activityGO:00083928.6CYP2B6, CYP2C8, CYP2C9

Sources for Cauda Equina Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet